News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


Lung cancer treatment takes another forward step

Note:  Embargoed until 6am, January 9, 2014

Media release

Lung cancer treatment takes another forward step            

Improvements in lung cancer treatment are set to continue with a PHARMAC decision to extend funding for erlotinib (Tarceva) from 1 January 2014.

Erlotinib and another similar drug gefitinib (Iressa) are tyrosine kinase inhibitors (TKIs) that have changed the way aggressive lung cancer is treated, and improved the prospects of people diagnosed with lung cancer.

Ministry of Health data shows that while colon cancer, prostate cancer, breast cancer and melanoma are most commonly diagnosed in New Zealand, the leading cause of cancer deaths is lung cancer.

TKIs are part of a new wave of targeted cancer medicines, which are particularly effective for patients with lung cancer that harbour a particular genetic sequence. Patients are identified using a diagnostic test called epidermal growth factor receptor (EGFR) testing. For people with this type of disease, targetted TKIs offer more effective, less toxic, and more convenient treatment.

Erlotinib was the first TKI to be funded in 2010, and since then access has been improved and widened so that from 1 January 2014, both erlotinib and gefitinib are funded for people who are newly diagnosed and who have not previously had platinum-based chemotherapy.

PHARMAC Deputy Medical Director Dilky Rasiah says the impact of the change in lung cancer treatments is becoming more apparent.

“For patients identified through testing, the TKIs have three major advantages over the chemotherapy treatments they are replacing,” she says.

“Firstly, and most importantly, they are more effective treatments for some patients. Usually when a new cancer drug or class of drugs becomes available, a three or four month improvement is considered a good advance. For the TKIs, the data show that the improvement in disease-free survival, the main marker for cancer treatment benefit, is 9-12 months. So this really is a significant improvement in lung cancer outcomes in New Zealand.”

“In addition to being more effective, TKIs don’t have a lot of the nasty side-effects compared with traditional platinum-based chemotherapy, which is very difficult for patients to tolerate. This means more people can maintain a good quality of life and continue on their treatment for longer, whereas previously people may have had to stop, or skip doses due to side effects, so again we get better outcomes.”


“The other benefit is convenience for patients. The TKIs are oral tablets that patients can collect from their pharmacy and take at home. By comparison, people had to make several journeys to a cancer treatment centre to receive an infusion of traditional chemotherapy. This could be difficult for people living some distance from a cancer treatment centre, and means people being treated with TKIs for cancer can carry on with life, and be with their families at a time when they need support.

“So, in short, having TKIs is a major advance in making effective treatment more available and convenient for patients.”

Dr Rasiah says the benefits also extend to other cancer patients not directly taking TKIs. Because the drugs can be taken at home, this frees up the hospital infusion services for other people needing cancer treatment, so that overall more people can receive funded cancer treatments in public hospitals.

PHARMAC’s decision to widen access to erlotinib, to become a first-line treatment for lung cancer, follows a price reduction by the supplier Roche.

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Architecture:
Ian Athfield Dies In Wellington

New Zealand Institute of Architects: It is with great sadness that we inform Members that Sir Ian Athfield, one of New Zealand's finest architects, has passed away in Wellington. More>>

ALSO:

Wellington Production: New-Look Tracy Brothers Are F.A.B.

ITV and New Zealand’s Pukeko Pictures today released an exclusive preview of the new-look Tracy brothers from this year’s hotly anticipated new series, Thunderbirds Are Go. More>>

ALSO:

Cardinal Numbers:
Pope Francis Names Archbishop From NZ Among New Cardinals

Announcing a list of bishops to be made Cardinals in February Pope Francis named Archbishop John Dew, Archbishop of Wellington, overnight from Rome. On hearing the news of the announcement, Archbishop John Dew said "This news is recognition of the Catholic Church in Aotearoa New Zealand, and the contribution it makes to the global Catholic family." More>>

ALSO:

Nomenclature: Charlotte And Oliver Top Baby Names For 2014

Charlotte and Oliver were the most popular names for newborn girls and boys in 2014... The top 100 girls’ and boys’ names make up a small proportion of the more than 12,000 unique first names registered for children born this year, says Jeff Montgomery, Registrar-General of Births, Deaths and Marriage. More>>

Werewolf: Katniss Joins The News Team

From the outset, the Hunger Games series has dwelt obsessively on the ways that media images infiltrate our public and personal lives... From that grim starting point, Mockingjay Part One takes the process a few stages further. There is very little of the film that does not involve the characters (a) being on screens (b) making propaganda footage to be screened and (c) reacting to what other characters have been doing on screens. More>>

ALSO:

Scoop Review Of Books: Ko Witi Te Kaituhituhi

Witi Ihimaera, the distinguished Māori author and the first Māori to publish a book of short stories and a novel, has adopted a new genre with his latest book. But despite its subtitle, this book is a great deal more than a memoir of childhood. More>>

Werewolf: Rescuing Paul Robeson

Would it be any harder these days, for the US government to destroy the career of a famous American entertainer and disappear them from history – purely because of their political beliefs? You would hope so. In 1940, Paul Robeson – a gifted black athlete, singer, film star, Shakespearean actor and orator – was one of the most beloved entertainers on the planet. More>>

ALSO:

"Not A Competition... A Quest": Chapman Tripp Theatre Award Winners

Big winners on the night were Equivocation (Promising Newcomer, Best Costume, Best Director and Production of the Year), Kiss the Fish (Best Music Composition, Outstanding New NZ Play and Best Supporting Actress), and Watch (Best Set, Best Sound Design and Outstanding Performance). More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news